KRMD (KORU Medical Systems) EBIT: $-2.59 Mil (TTM As of Mar. 2026)


KRMD KORU Medical Systems Inc KRMD
76 GF Score
Price $4.43
GF Value $4.08
Valuation Fairly Valued
View Full Analysis

What is KORU Medical Systems EBIT?

KORU Medical Systems KRMD -3.49% 76 EBIT is $-2.59 Mil as of Mar. 2026. GuruFocus rates KRMD with a GF Score™ of 76/100 and a GF Value™ of $4.08 (Fairly Valued).

KORU Medical Systems's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.87 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.59 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. KORU Medical Systems's annualized ROC % for the quarter that ended in Mar. 2026 was -29.79%. KORU Medical Systems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -33.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. KORU Medical Systems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.31%.


KORU Medical Systems  (NAS:KRMD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

KORU Medical Systems's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-3.46 * ( 1 - 0% )/( (11.7 + 11.531)/ 2 )
=-3.46/11.6155
=-29.79 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

KORU Medical Systems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.46/( ( (7.428 + max(2.821, 0)) + (7.193 + max(3.181, 0)) )/ 2 )
=-3.46/( ( 10.249 + 10.374 )/ 2 )
=-3.46/10.3115
=-33.55 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.89 + 3.678 + 0.909) - (7.628 + 0 + 0.028)
=2.821

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.983 + 4.476 + 1.026) - (8.293 + 0 + 0.011000000000001)
=3.181

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

KORU Medical Systems's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-2.593/198.081
=-1.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KORU Medical Systems EBIT Related Terms


KORU Medical Systems EBIT Historical Data

* Premium members only.

The historical data trend for KORU Medical Systems's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KORU Medical Systems EBIT Chart

KORU Medical Systems Annual Data
Trend Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.03 -10.78 -10.27 -6.45 -2.97

KORU Medical Systems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -0.31 -0.87 -0.55 -0.87

KRMD vs EMBC, PDEX, SMTI: EBIT Comparison

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KORU Medical Systems EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's EV-to-EBIT falls into.


KRMD
76GF Score
KORU Medical Systems Inc KRMD
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KORU Medical Systems EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-2.59 Mil mean?
KORU Medical Systems (KRMD) has a EBIT of $-2.59 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on KORU Medical Systems.
Is KORU Medical Systems' EBIT too high?
KORU Medical Systems' current EBIT is $-2.59 Mil. Overall, KORU Medical Systems has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' EBIT compare to EMBC and PDEX?
KORU Medical Systems' EBIT of $-2.59 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on KORU Medical Systems. KORU Medical Systems's current EBIT is $-2.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Fairly Valued. The stock's GF Value™ is $4.08, compared to a current price of $4.43 — trading 8.6% above its estimated fair value. The current EBIT is $-2.59 Mil. KORU Medical Systems' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current EBIT is $-2.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KORU Medical Systems (KRMD) Overvalued in 2026?

Based on GuruFocus' analysis, KORU Medical Systems stock appears to be overvalued. The current stock price of $4.43 is trading 8.6% above its estimated GF Value™ of $4.08. GuruFocus considers KORU Medical Systems to be Fairly Valued.

Key valuation signals for KRMD:

  • EBIT: $-2.59 Mil
  • GF Value™: $4.08 vs. price of $4.43 (8.6% above fair value)
  • GF Score™: 76/100

No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


KORU Medical Systems Business Description

Address 100 Corporate Drive, Mahwah, NJ, USA, 07430
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
76GF Score

Get the complete analysis for KRMD

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$4.08
GF Value